RYTM as reported
Rhythm Pharmaceuticals, Inc. reported $240M of revenue over the trailing twelve months, +54% on the year before. 10 reported series are charted on this page, each one as filed.
$240M
Revenue, trailing twelve months · to Q2 2026 · +54% against the twelve months before
- Net Income
- −$205M
Net Income · +12% year on year · trailing twelve months to Q2 2026
- Op Margin
- −85%
Op Margin · trailing twelve months to Q2 2026
- EPS
- −$3.11
EPS · +3.3% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $240M | +54% | Q2 2026 |
| Net Income | −$205M | +12% | Q2 2026 |
| EPS | −$3.11 | +3.3% | Q2 2026 |
| Gross Margin | 89% | n/a | Q2 2026 |
| Op Margin | −85% | n/a | Q2 2026 |
| Net Margin | −87% | n/a | Q2 2026 |
| ROE | −159% | n/a | Q2 2026 |
| ROA | −43% | n/a | Q2 2026 |
| ROIC | 118% | n/a | Q2 2026 |
| Free Cash Flow | −$136M | n/a | Q4 2023 · 10 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Rhythm Pharmaceuticals, Inc. (RYTM) - Revenue & ProfitRevenue & ProfitRhythm Pharmaceuticals, Inc. (RYTM)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com